Zhou, F. (2025). Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e15562